My Companies
Notification
Account
USFDA inspected Indoco’s Goa Plant II sterile facility from 27 August to 4 September 2026 and issued seven Form 483 observations. The company will submit a response within the stipulated timeframe. Context: the inspection does not yet resolve the plant’s longstanding regulatory overhang.
Indoco Remedies Promoter Group Buys 38,930 Shares In Open Market
Indoco Remedies Sells Mumbai Land Parcel For ₹64 Crore